The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Isocitrate Dehydrogenase Mutation and ( R )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development
Open accessAbstract
The identification of heterozygous mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) in subsets of cancers, including secondary glioblastoma, acute myeloid leukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, led to intense discovery efforts to delineate the mutations’ involvement in carcinogenesis and to develop therapeutics, which we review here. The three IDH isoforms (nicotinamide adenine dinucleotide phosphate–dependent IDH1 and IDH2, and nicotinamide adenine dinucleotide–dependent IDH3) contribute to regulating the circuitry of central metabolism. Several biochemical and genetic observations led to the discovery of the neomorphic production of the oncometabolite (R)-2-hydroxyglutarate (2-HG) by mutant IDH1 and IDH2 (mIDH). Heterozygous mutation of IDH1/2 and accumulation of 2-HG cause profound metabolic and epigenetic dysregulation, including inhibition of normal cellular differentiation, leading to disease. Crystallographic structural studies during the development of compounds targeting mIDH demonstrated common allosteric inhibition by distinct chemotypes. Ongoing clinical trials in patients with mIDH advanced hematologic malignancies have demonstrated compelling clinical proof-of-concept, validating the biology and drug discovery approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Once translocated, HIF-1α induces expression of downstream gene targets that regulate tumor cell growth, motility, invasion, and metastasis (82).”
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Research works printed but not linked: 2
- de Botton S, 2015, Haematologica, 100, 214
- Davis M, 2010, Probe Reports from the NIH Molecular Libraries Program
Cited by
Sorted by citations
Items 101–200 of 207
Luo, C., Shi, Y., Liu, Y., Liu, Q., Mao, M., Luo, M., Yang, K., Wang, W., Chen, C., Niu, Q., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00825-4 · Cited by 21
Rahban, M., Joushi, S., Bashiri, H., Saso, L., & Sheibani, V. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1325214 · Cited by 21
Palominos, C., Fuentes-Retamal, S., Salazar, J. P., Guzmán‐Rivera, D., Correa, P., Mellado, M., Araya‐Maturana, R., & Urra, F. A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216965 · Cited by 21
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer
Zarei, M., Lal, S., Gohar, A. V., O’Hayer, K., Gunda, V., Singh, P. K., Brody, J. R., & Winter, J. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0557 · Cited by 20
Ma, T., Zou, F., Pusch, S., Yang, L., Zhu, Q., Xu, Y., Gu, Y., von Deimling, A., & Zha, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.009 · Cited by 19
Cao, H., Zhu, G., Sun, L., Chen, G., Ma, X., Luo, X., & Zhu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111694 · Cited by 18
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma
Murnyák, B., & Huang, L. E. (2021) · Cells · doi:10.3390/cells10082116 · Cited by 18
Ma, L., Kong, F., Ma, Y., Guo, J., Wang, S., Dong, Z., Sun, A., Zou, Y., & Ge, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00699-0 · Cited by 16
Zou, F., Pusch, S., Hua, J., Ma, T., Yang, L., Zhu, Q., Xu, Y., Gu, Y., von Deimling, A., & Zha, X. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.030 · Cited by 17
An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
Verdura, S., Cuyàs, E., Lozano‐Sánchez, J., Bastidas-Velez, C., Llorach-Parés, L., Fernández‐Arroyo, S., Hernández‐Aguilera, A., Joven, J., Nonell‐Canals, A., Bosch‐Barrera, J., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy159 · Cited by 17
Slotting metabolomics into routine precision medicine
Mussap, M., Noto, A., Piras, C., Atzori, L., & Fanos, V. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1911639 · Cited by 18
Chen, X., & Ding, J. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102672 · Cited by 16
Zhao, L., Guo, J., Xu, S., Duan, M., Liu, B., Zhao, H., Wang, Y., Liu, H., Yang, Z., Yuan, H., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.04.016 · Cited by 18
Abundance of d ‐2‐hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1‐expressing cells
Kancharana, B., Katragunta, K., Sarma, U. M., & Jain, N. (2019) · FEBS Letters · doi:10.1002/1873-3468.13500 · Cited by 16
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma
Wang, Q.-X., Zhang, P.-Y., Li, Q., Tong, Z., Yu, S., Yu, Y., Yu, Y., Ding, N., Leng, X.-J., Chang, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115464 · Cited by 15
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
Lu, V. M., & McDonald, K. L. (2018) · CNS Oncology · doi:10.2217/cns-2017-0019 · Cited by 15
Li, C., Pu, B., Gu, L., Zhang, M., Shen, H., Yuan, Y., & Liao, L. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13078 · Cited by 15
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
Ivosidenib: an investigational drug for the treatment of biliary tract cancers
Angelakas, A., Lamarca, Á., Hubner, R. A., McNamara, M. G., & Valle, J. W. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1900115 · Cited by 15
Lee, C. L., O'Kane, G. M., Mason, W. P., Zhang, W.-J., Spiliopoulou, P., Hansen, A. R., Grant, R. C., Knox, J. J., Stockley, T. L., Zadeh, G. M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0460 · Cited by 14
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Wang, J., Zhang, Z.-G., Ding, Z., Dong, W., Liang, H.-F., Chu, L., Zhang, B.-X., & Chen, X. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.04.056 · Cited by 14
Fujii, J. (2024) · Free Radical Research · doi:10.1080/10715762.2024.2407147 · Cited by 13
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo
Jia, P., Wu, Y., Du, H., Yang, L., Zhang, Z., Ma, T., Sun, L., Yuan, S., Lu, L., & Zha, X. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105072 · Cited by 13
Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma
Garrett, M. C., Fujii, Y., Osaka, N., Ito, D., Hirota, Y., & Sasaki, A. T. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.gliomas.2021.chapter4 · Cited by 14
Bruce‐Brand, C., & Govender, D. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206813 · Cited by 13
Epigenetic regulation of inflammation by CxxC domain‐containing proteins*
Onodera, A., Kiuchi, M., Kokubo, K., & Nakayama, T. (2021) · Immunological Reviews · doi:10.1111/imr.13056 · Cited by 12
Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas
Hersh, D. S., Peng, S., Dancy, J. G., Galisteo, R., Eschbacher, J. M., Castellani, R. J., Heath, J. E., Legesse, T. B., Kim, A. J., Woodworth, G. F., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2799-3 · Cited by 12
Vadlakonda, L., Indracanti, M., Kalangi, S. K., Gayatri, B. M., Gajula, N. N., & Reddy, A. B. M. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00566-5 · Cited by 11
Wang, Q., Chen, M., Yang, B. J., Zheng, W., Liu, X., & Jian, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113766 · Cited by 14
Karabulutoglu, M., Finnon, R., Imaoka, T., Friedl, A. A., & Badie, C. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1490042 · Cited by 11
Urine metabolomics analysis of sleep quality in deep-underground miners: A pilot study
Wen, Q., Zhou, J., Sun, X., Ma, T., Liu, Y., Xie, Y., Wang, L., Cheng, J., Wen, J., Wu, J., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.969113 · Cited by 11
Enchondromatosis-associated oligodendroglioma: case report and literature review
Achiha, T., Arita, H., Kagawa, N., Murase, T., Ikeda, J., Morii, E., Kanemura, Y., Fujimoto, Y., & Kishima, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0303-y · Cited by 11
Gregorio, E. D., Miolo, G., Saorin, A., Steffan, A., & Corona, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115574 · Cited by 11
The Crucial Roles of Intermediate Metabolites in Cancer
Huang, S., Wang, Z., & Zhao, L. (2021) · Cancer Management and Research · doi:10.2147/cmar.s321433 · Cited by 11
Epigenetic control of gene expression by cellular metabolisms in plants
Huang, F., & He, Y. (2024) · Current Opinion in Plant Biology · doi:10.1016/j.pbi.2024.102572 · Cited by 11
Liu, S., Zhou, Y., Chen, Y., Qiao, Y., Bai, L., Zhang, S., Men, D., Zhang, H., Pan, F., Gao, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112828 · Cited by 10
Degrading mutant IDH1 employing a PROTAC-based approach impairs STAT3 activation
Dutta, H., & Jain, N. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110281 · Cited by 10
NAMPT Inhibition Induces Neuroblastoma Cell Death and Blocks Tumor Growth
Vallejo, F. A., Sanchez, A., Cuglievan, B., Walters, W. M., Angulo, G. D., Vanni, S., & Graham, R. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.883318 · Cited by 11
A Förster resonance energy transfer-based d-2-hydroxyglutarate biosensor
Xiao, D., Xu, X., Gao, K., Wang, M., Zhang, W., Lü, C., Wang, X., Wang, Q., Xu, P., Ma, C., et al. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133681 · Cited by 10
Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly
Chu, Y., Chen, C.-W. D., Lai, M., Lim, S., & Lin, W.-R. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i29.4499 · Cited by 12
Wu, C., Song, H., Fu, X., Li, S., & Jiang, T. (2020) · BioMed Research International · doi:10.1155/2020/1086792 · Cited by 10
Yang, Z., & Jiang, H. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03522-x · Cited by 10
Türkez, H., Tozlu, Ö. Ö., Arslan, M. E., & Mardinoğlu, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105168 · Cited by 12
Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
Lang, F., Jha, A., Meuter, L., Pacák, K., & Yang, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731096 · Cited by 10
Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
Hu, C., Zeng, Z., Ma, D., Yin, Z.-X., Zhao, S., Chen, T., Tang, L., & Zuo, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982375 · Cited by 9
Murali, P., & Ramanathan, K. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416523500023 · Cited by 9
Metabolic functions of misunderstood D-2-hydroxyglutarate
Liu, Y., Kang, Z., Zhang, W., Ma, C., Xu, P., & Gao, C. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100101 · Cited by 10
Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging
Gough, R., Treffy, R., Krucoff, M. O., & Desai, R. R. (2025) · Cancers · doi:10.3390/cancers17010124 · Cited by 12
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
Evans, L., Trinder, S. M., Dodgshun, A. J., Eisenstat, D. D., Whittle, J. R., Hansford, J. R., & Valvi, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1515538 · Cited by 10
Liu, X., Reinbold, R., Liu, S., Herold, R. A., Rabe, P., Duclos, S., Yadav, R. B., Abboud, M. I., Thieffine, S., Armstrong, F. A., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102873 · Cited by 8
Patel, S. H., Vasu, S., Guo, L., Lemaster, O., Byrd, J. C., & Walker, A. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7368 · Cited by 9
C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors
Viswanath, P., Li, Y., & Ronen, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_12 · Cited by 8
The yeast mitochondrial succinylome: Implications for regulation of mitochondrial nucleoids
Frankovský, J., Keresztesová, B., Bellová, J., Kunová, N., Čanigová, N., Hanáková, K., Bauer, J., Ondrovičová, G., Lukáčová, V., Siváková, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101155 · Cited by 8
Lam, F. C., Byun, J., Guru, S., AbuReesh, D., Hori, Y. S., Rahimy, E., Pollom, E. L., Soltys, S. G., Park, D. J., & Chang, S. D. (2025) · Brain Sciences · doi:10.3390/brainsci15060649 · Cited by 7
The Interplay of Aging and Cancer: Mechanisms, Implications, and Therapeutic Strategies
Wang, L., Luo, Y., Chen, X., Wang, Y., & Zhang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70041 · Cited by 8
Gai, C., Zeng, H., Xu, H., Chai, X., Zou, Y., Zhuang, C., Ge, G., & Zhao, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117041 · Cited by 7
Cai, R., Lin, H., Cheng, Q., Mao, Q., Zhang, C., & Tan, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01526-8 · Cited by 7
Valvi, S., Fouladi, M., Fisher, M. J., & Gottardo, N. G. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1662414 · Cited by 12
Zhang, N., Zheng, B., Yao, X., Huang, X., Du, J., Shen, Y., Huang, Z., Chen, J., Lin, Q., Lan, W., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.112 · Cited by 6
Garcia, I., Cornely, K. A., Peterson, C. N., & Berkmen, M. B. (2024) · Essays in Biochemistry · doi:10.1042/ebc20230077 · Cited by 8
Pérez, A., Rivoira, M. A., Rodríguez, V. A., Marchionatti, A. M. E., & de Talamoni, N. T. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0561 · Cited by 6
A genetically encoded biosensor for point-of-care and live-cell detection of d-2-hydroxyglutarate
Liu, Y., Kang, Z., Xu, R., Hou, S., Gong, L., Guo, L., Gao, K., Xu, X., Tan, X., Xiao, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62225-8 · Cited by 5
Genomic Biomarker Assessment in Gliomas
Lim-Fat, M.-J., Nayak, L., & Meredith, D. M. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2020.02.003 · Cited by 5
Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate
Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 5
Mutations in DNA Methyltransferases and Demethylases
Sun, X., Chen, Z., & Chen, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65054-7 · Cited by 4
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4
Chen, M., Xu, J., Chen, F., Zhou, Q., Wang, S., & Han, A. (2022) · Acta Chromatographica · doi:10.1556/1326.2022.01053 · Cited by 3
Kurimoto, M., Rockenbach, Y., Kato, A., & Natsume, A. (2023) · Genes · doi:10.3390/genes14061201 · Cited by 3
Pierangeli, S., Donnini, S., Ciaurro, V., Milano, F., Cardinali, V., Sciabolacci, S., Cimino, G., Gionfriddo, I., Ranieri, R., Cipriani, S., et al. (2024) · Cancers · doi:10.3390/cancers16152675 · Cited by 4
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Dal-Bekar, N. E., Tuna, G., İşlekel, S., & İşlekel, H. (2022) · Bioanalysis · doi:10.4155/bio-2022-0168 · Cited by 2
Hypotaurine promotes glioma cell invasion by hypermethylating the Wnt5a promoter
Tian, H., Chu, X., Guan, Q., Liu, J., & Liu, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0312055 · Cited by 2
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan
Naz, H., Bashir, Q., Rashid, N., & Shahzad, N. (2020) · Annals of Human Genetics · doi:10.1111/ahg.12409 · Cited by 1
Sahasrabudhe, K. D., Zhao, W., Berg, M., & Bhatnagar, B. (2023) · Frontiers in Hematology · doi:10.3389/frhem.2023.1134837 · Cited by 1
A bacterial enzyme may correct 2-HG accumulation in human cancers
Yin, W. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235191 · Cited by 1
Blocking mutant IDH1 phosphorylation triggers APC/C CDH1-dependent ubiquitination in mitotic cells
Swain, S., & Jain, N. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120002 · Cited by 1
Udutha, S., Batsios, G., Taglang, C., Gillespie, A. M., & Viswanath, P. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag063 · Cited by 1
Molecular Classification of Diffuse Gliomas
Kaur, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98296 · Cited by 1
Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomasPreprint
Taglang, C., Batsios, G., Gillespie, A. M., Phillips, J. J., Taylor, J. W., & Viswanath, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.30.673205 · Cited by 1
Mitochondria Remodeling in Cancer
Dornfeld, K. J., & Skildum, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_9
Intracytoplasmic lipid droplets in high grade glioma : metabolism and target for therapy
Murren, R. (2018) · University of Birmingham Institutional Research Archive (University of Birmingham)
The Effects of Exercise on LINE-1 Regulation
Romero, M. A. (2019)
Patent Highlights June–July 2020
Mucke, H. A. (2020) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2020-0027
Investigating Covid- 19 and Prophylactive Measures to Contain Spread of the Disease
Mustapha, B., & Usman, R. Z. (2021) · Journal of Biology Agriculture and Healthcare · doi:10.7176/jbah/11-4-05
An Innovation 10 Years in the Making: The Stories in the Pages of ACS Medicinal Chemistry Letters
Altman, R. A., Brai, A., Golden, J. E., Regina, G. L., Li, Z., Moore, T. W., Pomerantz, W. C. K., Rajapaksa, N. S., & Adams, A. M. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00623
Wang, Y., Wu, Y., Zhang, X., Ma, Q., Zhong, D.-B., Gao, Y., Feng, Y., Li, Y., Yin, J., & Yang, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4144893
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00002-7
Xu, N., Wu, K., La, T., & Cao, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35617
Multi-targeted Tyrosine Kinase Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders
Belgin Sever, E. A., Ciftci, H. I., Sever, B., Saso, L., Tzoneva, R., & Onnis, V. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-5295-7
Research Progress in Targeted Therapy for Cholangiocarcinoma
牛, 蒙. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482383
Advances in Genomics and Epigenetics of Glioma
Yang, H., & Chen, L. (2024) · Experts' Perspectives on Medical Advances. · doi:10.1007/978-981-99-0123-4_6
Mitochondria as a Key Player in Cancer
Čižmárová, B., Hubková, B., Grešová, A., Kraus, V., & Birková, A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_387
Koju, N., Zhou, M., & Sheng, R. (2025) · Springer eBooks · doi:10.1007/978-981-97-9877-3_37
Molecularly driven therapies in the treatment of primary brain tumors
Nasany, R. A., & de la Fuente, M. I. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.05.005
Habiba, U., Sugino, H., Yordanova, R., Ise, K., Tanei, Z.-I., Ishida, Y., Tanikawa, S., Terasaka, S., Sato, K.-I., Kamoshima, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14642873
Hereditary cancer syndromes linked to oxidative phosphorylation insufficiency
Kaplan, B., Duraj, T., Lee, D. C., & Seyfried, T. N. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0301
Asiri, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1818483
Metadata
- Authors
- Dang, L., & Su, S.-S. M.
- Affiliations
- Agios Pharmaceuticals (United States) (US)
- ORCID
- Dang, Lenny
- Venue
- Annual Review of Biochemistry
- Publisher
- Annual Reviews
- Published
- 2017-06-20
- Volume
- 86
- Issue
- 1
- Pages
- 305-331
- ISSN
- 0066-4154 (ISSN-L)
- 1545-4509
- OpenAlex
- W2556519788
- Cited by
- 204
- References
- 109
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 20 · 2023: 17 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 23 · 2018: 33 · 2017: 10
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annual Review of Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agios Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- isocitrate dehydrogenase, IDH1 mutation, IDH2 mutation, (R)-2-hydroxyglutarate, oncometabolites, allosteric inhibition, IDH inhibitors, epigenetic dysregulation, secondary glioblastoma, acute myeloid leukemia, cholangiocarcinoma, chondrosarcoma, central carbon metabolism, hematologic malignancies, drug development
- MeSH terms
- Acetamides, Antineoplastic Agents, Benzimidazoles, Enzyme Inhibitors, Glutarates, Humans, Imidazoles, Isocitrate Dehydrogenase, Isoenzymes, Models, Molecular, Mutation, Biomarkers, Tumor, Leukemia, Myeloid, Acute, Gene Expression, Benzeneacetamides, Small Molecule Libraries, Drug Discovery, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
